Search Result

Results for "

and CDK2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (1) Akt (3) Anaplastic lymphoma kinase (ALK) (2) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (48) ATM/ATR (1) Aurora Kinase (2) Autophagy (7) Bacterial (1) Bcl-2 Family (1) c-Kit (1) Calcium Channel (1) Carbonic Anhydrase (4) Casein Kinase (1) Caspase (2) CDK (186) CFTR (1) Checkpoint Kinase (Chk) (2) Cholinesterase (ChE) (1) COX (1) CXCR (2) Cyclin G-associated Kinase (GAK) (1) DNA/RNA Synthesis (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (10) Endogenous Metabolite (1) Enterovirus (1) ERK (2) FAK (1) FGFR (1) FLT3 (6) GSK-3 (17) HDAC (2) HIV (2) IKK (1) JAK (6) JNK (3) Ligands for Target Protein for PROTAC (1) LIM Kinase (LIMK) (1) MAPKAPK2 (MK2) (2) MDM-2/p53 (1) MEK (2) Microtubule/Tubulin (2) Molecular Glues (3) mTOR (2) Necroptosis (1) NEKs (1) P-glycoprotein (1) Parasite (1) PARP (1) Phosphatase (1) PI3K (5) Pim (1) PKA (1) PKC (6) PKD (1) PROTAC Linkers (2) PROTACs (9) Reactive Oxygen Species (1) Reverse Transcriptase (1) ROS Kinase (1) Salt-inducible Kinase (SIK) (1) Small Interfering RNA (siRNA) (5) SphK (2) Src (2) Topoisomerase (2) Trk Receptor (1) VEGFR (5) Wee1 (2)
By Research Areas:	Cancer (193) Cardiovascular Disease (3) Infection (3) Inflammation/Immunology (10) Metabolic Disease (3) Neurological Disease (13)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Pre-designed siRNA Sets (5) siRNAs (5)

215

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162255

CDK2-IN-23	CDK	Cancer
CDK2-IN-23 (Compound 17) is a kinase selective and highly potent *CDK2* inhibitor (IC₅₀ = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .

HY-W478102

CDK2-IN-13	CDK	Cancer
CDK2-IN-13 (Compound 15) is a *CDK2* inhibitor with an IC₅₀ of 12 µM. CDK2-IN-13 can be used in research of cancer .

HY-143497

*HDAC1/2 and* CDK2-IN-1**	HDAC CDK Apoptosis	Cancer
HDAC1/2 and CDK2-IN-1 (compound 14d) is a potent HDAC1, HDAC2 and *CDK2* dual inhibitor, with IC₅₀ values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induce apoptosis. HDAC1/2 and CDK2-IN-1 exhibits desirable in vivo antitumor activity .

HY-144810

CDK2-IN-8	CDK	Cancer
CDK2-IN-8 is a potent *CDK2* inhibitor with an IC₅₀ of 1.74 µM. CDK2-IN-8 shows antiproliferative activity. CDK2-IN-8 has the potential for the research of melanoma .

HY-160643

CDK2-IN-27	CDK	Cancer
CDK2-IN-27 (compound 1) is a potent *CDK2* inhibitor with IC₅₀ values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .

HY-144811

CDK2-IN-9	CDK Apoptosis	Cancer
CDK2-IN-9 is a potent *CDK2* inhibitor with an IC₅₀ of 0.63 µM. CDK2-IN-9 shows antiproliferative activity. CDK2-IN-9 induces apoptosis and cell cycle arrest at S and G2/M phase. CDK2-IN-9 has the potential for the research of melanoma .

HY-151580

CDK2-IN-14	CDK	Cancer
CDK2-IN-14 (compound 4f) is a highly selective *CDK2* inhibitor. CDK2-IN-14 can be used in research of cancer .

HY-164664

CDK2-IN-30	CDK	Cancer
CDK2-IN-30 (Formula (I)) is a *CDK2* inhibitor with an IC₅₀ value ≤20 nM. CDK2-IN-30 can be used in tumor research .

HY-159805

CDK2-IN-31	CDK	Cancer
CDK2-IN-31 (compound I-125A) is a *CDK2* inhibitor. CDK2-IN-31 can be used in cancer research .

HY-148651

CDK2-IN-15	CDK	Cardiovascular Disease Cancer
CDK2-IN-15 (Compound 19) is an inhibitor of *CDK2* with an IC₅₀ of 2.9 μM. CDK2-IN-15 can be used for cancer research .

HY-163815

CDK2 degrader 2	PROTACs CDK	Others
CDK2 degrader 2 is a PROTAC class *CDK2* degrader. The CDK2 binding moiety (CBM) binds to the *CDK2* protein and subsequently undergoes ubiquitination, leading to the degradation of *CDK2* through the ubiquitin proteasome pathway (UPP). CDK2 degrader 2 can cause degradation of *CDK2* in MKN1 cells, with a DC₅₀ value less than 100 nM and an average D_max value greater than 75%. (Red: CBM; Blue: DIM; Black: linker)

HY-163357

CDK2/MDM2-IN-1	CDK MDM-2/p53	Cancer
CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC₅₀ value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .

HY-139651

CDK2-IN-7	CDK	Cancer
CDK2-IN-7 is a *CDK2* inhibitor for researching cancer (IC₅₀ < 50 nM).

HY-160556

CDK2-IN-26	CDK	Cancer
CDK2-IN-26 (compound 9) is a potent inhibitor of CDK2 .

HY-155441

CDK2-IN-20	CDK	Cancer
CDK2-IN-20 (compound 3b) is an inhibitor of *CDK2. CDK2-IN-20 has cytotoxicity* on tumor cells presenting an IC₅₀ range of 5.52-17.09 µM. CDK2-IN-20 arrests the MCF-7 cell cycle at the S phase and induces apoptosis .

HY-151580S

CDK2-IN-14-d3	CDK	Cancer
CDK2-IN-14-d₃ is a potent and selective CDK2 inhibitor. CDK2-IN-14-d₃ can be used in research of cancer[1].

HY-155966

CDK2-IN-19	CDK	Cancer
CDK2-IN-19 (Compound 32) is a selective and orally active *CDK2* inhibitor (K_i: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors .

HY-150573

CDK2-IN-12	CDK Carbonic Anhydrase	Cancer
CDK2-IN-12 (compound 10b) is a potent *CDK2* inhibitor, with an IC₅₀ of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with K_I values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .

HY-112460

CDK2-IN-3	CDK	Cancer
CDK2-IN-3 (compound 3) is a potent and selective *CDK2* inhibitor with an IC₅₀ of 60 nM .

HY-169246

CDK2-IN-32	CDK Apoptosis	Cancer
CDK2-IN-32 (Compound 5g) is a selective *CDK2* inhibitor with an IC₅₀ of 0.21 μM. CDK2-IN-32 shows cytotoxicity against Vero cells with an IC₅₀ of 28.52 μM .

HY-161291

CDK2-IN-25	CDK	Cancer
CDK2-IN-25 (compound 7e) is a CDK2 inhibitor with an IC₅₀ of 0.149 μM .

HY-168057

*PROTAC CDK2* Degrader-1**	PROTACs CDK	Cancer
PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader for cyclin-dependent kinase 2 (CDK2). PROTAC CDK2 Degrader-1 inhibits the phosphorylation of RB protein in CDK2 dependent cell line OVCAR3 with an IC₅₀ of 100-500 nM .

HY-161463

CDK2-IN-28	CDK	Cancer
CDK2-IN-28 (compound 22) is a *CDK2* inhibitor with good selectivity and cellular effects against other CDKs. CDK2-IN-28 has anti-proliferative effects on MKN1 cells (EC50: 0.31 μM) .

HY-155602

CDK2-IN-18	CDK	Cancer
CDK2-IN-18 (compound 8q) is a potent inhibitor of *CDK2/E* and CDK4/D1, with IC₅₀s of 8 nM and 46 nM, respectively. CDK2-IN-18 inhibits the proliferation of tumor cells .

HY-151573

*EGFR/CDK2-IN-1*	EGFR CDK	Cancer
EGFR/CDK2-IN-1 (Compound 3b) is an *EGFR/CDK2* inhibitor. EGFR/CDK2-IN-1 shows good cytotoxicity against MCF7 and HepG2 cells. EGFR/CDK2-IN-1 can be used in cancer research .

HY-164827

CDK2 degrader 3	CDK	Cancer
CDK2 degrader 3 can selectively degrade *CDK2* and has anti-tumor activity .

HY-163814

CDK2 degrader 1	PROTACs CDK	Cancer
CDK2 degrader 1 (Compound 3) is an orally active cyclin-dependent kinase 2 (CDK2) degrader based on PROTAC technology. CDK2 degrader 1 binds to cereblon to induce ubiquitination and subsequent proteasomal degradation of the *CDK2. CDK2* degrader 1 is used in the research of a wide range of cancers (Red: spiro[3.3]heptan-2- ylmethyl carbonochloridate; Blue: N,N-diisopropylethylamine; Black: linker) .

HY-117535

CDK2-IN-4 2 Publications Verification	CDK	Cancer
CDK2-IN-4 (compound 73) is a potent and selective *CDK2* inhibitor with an IC₅₀ of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC₅₀=86 uM) .

HY-159155

CDK2/4-IN-1	CDK Microtubule/Tubulin	Cancer
CDK2/4-IN-1 (compound B-4a) is a *CDK2/4* inhibitor and a tubulin polymerization inhibitor. CDK2/4-IN-1 can be used in cancer research .

HY-150572

CDK2-IN-11	CDK Carbonic Anhydrase	Cancer
CDK2-IN-11 (compound 9d) is a potent *CDK2* inhibitor with an IC₅₀ of 6.4 μM, and K_I values of 23.4 nM, 56.3 nM and 44.3 nM for hCA II, hCA IX and hCA XII, respectively. CDK2-IN-11 can be used for researching anticancer .

HY-169048

CDK2/4-IN-2	CDK	Cancer
CDK2/4-IN-2 (compound 56) is a *CDK2* and CDK4 dual inhibitor with IC₅₀s less than 100 nM. CDK2/4-IN-2 can be used in the study of cancer .

HY-P3730

Cdk2/Cyclin Inhibitory Peptide I	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a *CDK2* inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-P3731

Cdk2/Cyclin Inhibitory Peptide II	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a *CDK2* inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-149436

CDK2/Bcl2-IN-1	CDK	Cancer
CDK2/Bcl2-IN-1 (compound 1), a saponin and a CDK-2 inhibitor (IC₅₀=117.6 nM) with promising cytotoxicity against cancer cells. CDK2/Bcl2-IN-1 also inhibits Bcl-2, and induces apoptosis in A549 lung cancer cells .

HY-148213

CDK2/4/6-IN-1	CDK	Cancer
CDK2/4/6-IN-1(example 29) is a *CDK2/4/6* inhibitor with IC₅₀ values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-123045

PNU-292137	CDK	Cancer
PNU-292137 is an orally active, potent *CDK2* inhibitor with IC₅₀s of 37 nM and 92 nM for CDK2/cyclin A and CDK2/cyclin E, respectively. PNU-292137 makes interactions with the hydrophobic pocket at the back of the CDK2 ATP pocket. PNU-292137 efficiently inhibits tumor cell proliferation in human colon and prostate tumor cell lines. PNU-292137 exhibits antitumor activity (TGI>50%) in a mouse xenograft model .

HY-156114

*EGFR/CDK2-IN-2*	EGFR CDK	Cancer
EGFR/CDK2-IN-2 (compound 6a) is a dual inhibitor of EGFR and CDK-2 with IC₅₀s of 19.6 and 87.9 nM, respectively. EGFR/CDK2-IN-2 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-2 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC₅₀ of 0.39 μM .

HY-156115

*EGFR/CDK2-IN-3*	EGFR CDK	Cancer
EGFR/CDK2-IN-3 (compound 4b) is a dual inhibitor of EGFR and CDK-2 with IC₅₀s of 71.7 and 113.7 nM, respectively. EGFR/CDK2-IN-3 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-3 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC₅₀ of 3.16 μM .

HY-156116

*EGFR/CDK2-IN-4*	EGFR CDK	Cancer
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor of EGFR and CDK-2 with IC₅₀s of 89.6 and 165.4 nM, respectively. EGFR/CDK2-IN-4 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-4 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC₅₀ of 2.74 μM .

HY-134622

*GSK-3/CDK5/CDK2-IN-1*	CDK GSK-3	Neurological Disease Cancer
GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of cdk5, *cdk2, and GSK-3* extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1 can be used for the research of cancer, and neurodegenerative diseases .

HY-15004

AUZ 454 4 Publications Verification K03861	CDK	Cancer
AUZ 454 (K03861) is a type II *CDK2* inhibitor with K_d of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.

HY-120497

PKCζ-IN-1	PKC CDK	Cancer
PKCζ-IN-1 is a compound that inhibits PKCζ and CDK2, showing an IC50 value of 5.18 nM for PKCζ and 1.04 μM for CDK2, with significant selectivity of 200-fold. PKCζ-IN-1 can reduce the activity of CDK2 while inhibiting PKCζ.

HY-157516

CDK2-IN-22	CDK	Cancer
CDK2-IN-22 (compound 7I) is a potent *CDK2* inhibitor with an IC₅₀ of 64.42 nM. CDK2-IN-22 presents a broad antiproliferative efficacy toward diverse cancer cells MV4-11, HT-29, MCF-7, and HeLa with IC₅₀ values of 0.83 μM, 2.12 μM, 3.12 μM, and 8.61 μM, respectively .

HY-RS02374

CDK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
CDK2 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK2 Human Pre-designed siRNA Set A CDK2 Human Pre-designed siRNA Set A

HY-RS02375

Cdk2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk2 Mouse Pre-designed siRNA Set A Cdk2 Mouse Pre-designed siRNA Set A

HY-RS02376

Cdk2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk2 Rat Pre-designed siRNA Set A Cdk2 Rat Pre-designed siRNA Set A

HY-161776

*P-gp/CDK2-IN-1*	P-glycoprotein CDK	Cancer
P-gp/CDK2-IN-1 (Compound 4j) is an inhibitor for is inhibitor for P-glycoprotein (P-gp) and for cyclin-dependent kinase-2 (CDK2). P-gp/CDK2-IN-1 inhibits the proliferation of cancer cells SW-480 and MCF-7 wit IC₅₀ of 38.6 μM and 26.6 μM. P-gp/CDK2-IN-1 exhibits antioxidant efficacy with EC₅₀ of 580 μM in DPPH experiment .

HY-112468

PNU112455A hydrochloride	CDK	Cancer
PNU112455A hydrochloride is an ATP-competitive *CDK2* and CDK5 inhibitor. PNU112455A hydrochloride binds to the ATP site of CDK2 and CDK5 with K_ms of 3.6 and 3.2 μM, respectively .

HY-15339

CVT-313 5+ Cited Publications CDK2 Inhibitor III	CDK	Cancer
CVT-313 (Cdk2 Inhibitor III) is a potent, selective, reversible, and ATP-competitive inhibitor of *CDK2* with IC₅₀ of 0.5 μM. CVT-313 inhibits CDC5L phosphorylation .

HY-130709

*PROTAC CDK2/9 Degrader-1*	PROTACs CDK	Cancer
PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for *CDK2* (DC₅₀=62 nM) and CDK9 (DC₅₀=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC₅₀=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand .

Cat. No.	Product Name	Target	Research Area

HY-P0235

*CDK2*	Peptides	Cancer
CDK2 is a member of the eukaryotic S/T protein kinase family and its function is to catalyze the phosphoryl transfer of ATP γ-phosphate to serine or threonine hydroxyl (denoted as S₀/T₀) in a protein substrate.

HY-P3730

Cdk2/Cyclin Inhibitory Peptide I	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a *CDK2* inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-P10324

TAT-p16 p16^INK4a peptide	Peptides	Cancer
TAT-p16 (p16INK4a peptide) is a peptide mimic of p16INK4a that can induce an early G phase cell cycle arrest in the absence of active cyclin E:Cdk2 complex .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N5072

Desmethylglycitein 1 Publications Verification 4',6,7-Trihydroxyisoflavone	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Source classification Phenols Polyphenols Plants Disease Research Fields Isoflavones Cancer	CDK PI3K PKC
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and *CDK2* in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-18981

Decursin 1 Publications Verification (+)-Decursin	Structural Classification Classification of Application Fields Source classification Coumarins Phenylpropanoids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Echinacea angustifolia DC.	PKC Apoptosis CXCR
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

HY-W019806

Lacto-N-fucopentaose I LNFP I	Infection Structural Classification Natural Products Polysaccharides Classification of Application Fields Animals Inflammation/Immunology Disease Research Fields Saccharides	Endogenous Metabolite CDK Reactive Oxygen Species Apoptosis Enterovirus Bacterial
Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote *CDK2* and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development .

HY-149436

CDK2/Bcl2-IN-1	Structural Classification Terpenoids Zygophyllaceae Source classification Diterpenoids Plants Zygophyllum album L.f.	CDK
CDK2/Bcl2-IN-1 (compound 1), a saponin and a CDK-2 inhibitor (IC₅₀=117.6 nM) with promising cytotoxicity against cancer cells. CDK2/Bcl2-IN-1 also inhibits Bcl-2, and induces apoptosis in A549 lung cancer cells .

HY-18981R

Decursin (Standard)	Structural Classification Source classification Coumarins Phenylpropanoids Umbelliferae Plants Echinacea angustifolia DC.	PKC Apoptosis CXCR
Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities [4].

Cat. No.	Product Name	Chemical Structure